1. |
Browning DJ, Stewart MW, Lee C. Diabetic macular edema: evidence-based management[J]. Indian J Ophthalmol, 2018, 66(12): 1736-1750. DOI: 10.4103/ijo.IJO_1240_18.
|
2. |
García Layana A, Adán A, Ascaso FJ, et al. Use of intravitreal dexamethasone implants in the treatment of diabetic macular edema: expert recommendations using a Delphi approach[J]. Eur J Ophthalmol, 2020, 30(5): 1042-1052. DOI: 10.1177/1120672119861623.
|
3. |
Chin EK, Almeida DRP, Velez G, et al. Ocular hypertension after intravitreal dexamethasone (Ozurdex) sustained-release implant[J]. Retina, 2017, 37(7): 1345-1351. DOI: 10.1097/IAE.0000000000001364.
|
4. |
中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2013年版)[J]. 中华糖尿病杂志, 2014, 6(7): 447-498. DOI: 10.3760/cma.j.issn.1674-5809.2014.07.004.Chinese Diabetes Society of Chinese Medical Association. The prevention guidelines for type 2 diabetes mellitus in China[J]. Chin J Diabetes Mellitus, 2014, 6(7): 447-498. DOI: 10.3760/cma.j.issn.1674-5809.2014.07.004.
|
5. |
Dot C, El Chehab H, Russo A, et al. Ocular hypertension after intravitreal steroid injections: clinical update as of 2015[J]. J Fr Ophtalmol, 2015, 38(7): 656-664. DOI: 10.1016/j.jfo.2015.03.002.
|
6. |
Pérez-Sarriegui A, Casas-Llera P, Díez-Álvarez L, et al. Phaco-non-penetrating deep sclerectomy in ocular hypertension secondary to dexamethasone intravitreal implant[J]. Arch Soc Esp Oftalmol (Engl Ed), 2018, 93(12): 580-585. DOI: 10.1016/j.oftal.2018.06.011.
|
7. |
Billant J, Agard E, Douma I, et al. Use of selective laser trabeculoplasty as an alternative in patients who developed ocular hypertension after intravitreal dexamethasone implants: a series of 35 eyes[J]. Graefe’s Arch Clin Exp Ophthalmol, 2022, 260(11): 3665-3673. DOI: 10.1007/s00417-022-05725-3.
|
8. |
Raj P, Kumar K, Balasubramaniam S, et al. Intraocular pressure fluctuation following intravitreal dexamethasone implant and incidence of secondary ocular hypertension: a Zambian perspective[J]. Pan Afr Med J, 2021, 39: 108. DOI: 10.11604/pamj.2021.39.108.23528.
|
9. |
Malclès A, Dot C, Voirin N, et al. The SAFODEX study. Incidence and risk factors of ocular hypertension[J]. Retina, 2017, 37(7): 1352-1359. DOI: 10.1097/IAE.0000000000001369.
|
10. |
Rezkallah A, Mathis T, Abukhashabah A, et al. Long-term incidence and risk factors of ocular hypertension following dexamethasone-implant injections: the safodex-2 study[J]. Retina, 2021, 41(7): 1438-1445. DOI: 10.1097/IAE.0000000000003080.
|
11. |
Choi W, Bae HW, Choi EY, et al. Age as a risk factor for steroid-induced ocular hypertension in the non-paediatric population[J]. Br J Ophthalmol, 2020, 104(10): 1423-1429. DOI: 10.1136/bjophthalmol-2019-314559.
|
12. |
Sudhalkar A, Kodjikian L, Chhablani J, et al. Intraocular dexamethasone implant position in situ and ocular hypertension[J]. Retina, 2018, 38(12): 2343-2349. DOI: 10.1097/IAE.0000000000001883.
|
13. |
Hymowitz MB, Chang D, Feinberg EB, et al. Increased intraocular pressure and hyperglycemic level in diabetic patients[J/OL]. PLoS One, 2016, 11(3): e0151833[2016-03-22]. https://europepmc.org/article/MED/27002725. DOI: 10.1371/journal.pone.0151833.
|
14. |
Hanyuda A, Sawada N, Yuki K, et al. Relationships of diabetes and hyperglycaemia with intraocular pressure in a Japanese population: the JPHC-NEXT Eye Study[J]. Sci Rep, 2020, 10(1): 5355. DOI: 10.1038/s41598-020-62135-3.
|
15. |
Shirakami T, Yamanaka M, Fujihara J, et al. Advanced glycation end product accumulation in subjects with open-angle glaucoma with and without exfoliation[J]. Antioxidants (Basel), 2020, 9(8): 755. DOI: 10.3390/antiox9080755.
|
16. |
周玉娟, 张杰, 孙先勇, 等. 高度近视性黄斑裂孔玻璃体切割术后早期高眼压的药物治疗[J]. 国际眼科杂志, 2015, 15(12): 2110-2113. DOI: 10.3980/j.issn.1672-5123.2015.12.23.Zhou YJ, Zhang J, Sun XY, et al. Drug treatment for high IOP at early stage after vitrectomy for macular hole caused by high myopia[J]. Int Eye Sci, 2015, 15(12): 2110-2113. DOI: 10.3980/j.issn.1672-5123.2015.12.23.
|
17. |
Choi W, Kim JD, Bae HW, et al. Axial length as a risk factor for steroid-induced ocular hypertension[J]. Yonsei Med J, 2022, 63(9): 850-855. DOI: 10.3349/ymj.2022.63.9.850.
|